TRIAL OF GP47779 (NHD OF OXCARBAZEPINE) ADMINISTERED IV TO INPATIENTS

GP47779（奥卡西平 NHD）对住院患者静脉注射的试验

• 批准号: 6265423
• 负责人: STEVEN C. SCHACHTER
• 金额: $ 2.98万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265423
• 关键词: anticonvulsants; brain disorder chemotherapy; clinical research; clinical trial phase I; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; intravenous administration; partial seizure; placebos

To evaluate the efficacy, safety and tolerability of monotherapy GP-47779 versus placebo, administered IV up to seven days in patients with refractory partial-onset seizures with or without secondarily generalized seizures, who are undergoing an inpatient presurgical diagnostic evaluation for epilepsy surgery.

为了评估单药治疗GP-47779对安慰剂的疗效，安全性和耐受性，对患有或没有次要概括性癫痫发作的难治性部分发作性癫痫发作的患者进行了长达7天的IV，这些患者正在接受患病治疗的癫痫病前诊断。